{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2","upperLimit":"9.2","value":"4.7"},{"groupId":"OG001","lowerLimit":"2.0","upperLimit":"4.2","value":"3.8"},{"groupId":"OG002","lowerLimit":"1.7","upperLimit":"13.1","value":"1.9"},{"groupId":"OG003","lowerLimit":"1.8","upperLimit":"5.6","value":"3.9"},{"comment":"Subject had a progression event; the Kaplan-Meier estimated median duration of clinical benefit times was not estimable.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"NA = not estimable. Data are not estimable due to insufficient number of participants with events.","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"6.0"},{"comment":"NA = not estimable. Data are not estimable due to insufficient number of participants with events.","groupId":"OG006","lowerLimit":"NA","upperLimit":"NA","value":"3.7"},{"comment":"NE = not estimable. Data are not estimable due to insufficient number of participants with events.","groupId":"OG007","lowerLimit":"1.9","upperLimit":"NA","value":"2.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"5"}],"units":"Participants"}],"description":"Duration of Clinical Benefit (DoCB) includes patients with a Best Overall Response of CR, PR, or SD and is defined as the time from the first tumor assessment of CR, PR or SD to the time of PD or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"300mg DKN-01 monotherapy in recurrent EEC. DKN-01 administered by IV infusion.","id":"OG000","title":"DKN-01 Monotherapy in Recurrent EEC"},{"description":"300mg DKN-01+paclitaxel in recurrent EEC. DKN-01 and paclitaxel administered by IV infusion.","id":"OG001","title":"DKN-01 + Paclitaxel in Recurrent EEC"},{"description":"300mg DKN-01 monotherapy in recurrent EOC. DKN-01 administered by IV infusion.","id":"OG002","title":"DKN-01 Monotherapy in Recurrent EOC"},{"description":"300mg DKN-01+paclitaxel in recurrent EOC. DKN-01 and paclitaxel administered by IV infusion.","id":"OG003","title":"DKN-01 + Paclitaxel in Recurrent EOC"},{"description":"300mg DKN-01 in carcinosarcoma. DKN-01 administered by IV infusion.","id":"OG004","title":"DKN-01 300mg Monotherapy in Carcinosarcoma"},{"description":"600mg DKN-01 monotherapy in carcinosarcoma. DKN-01 administered by IV infusion.","id":"OG005","title":"DKN-01 600mg Monotherapy in Carcinosarcoma"},{"description":"300mg DKN-01 + paclitaxel in carcinosarcoma. DKN-01 and paclitaxel administered by IV infusion.","id":"OG006","title":"DKN-01 300mg + Paclitaxel in Carcinsarcoma"},{"description":"600mg DKN-01 + paclitaxel in carcinosarcoma. DKN-01 and paclitaxel administered by IV infusion.","id":"OG007","title":"DKN-01 600mg + Paclitaxel in Carcinosarcoma"}],"paramType":"MEDIAN","populationDescription":"Number of participants analyzed only includes patients who had CR, PR, or SD.","reportingStatus":"POSTED","timeFrame":"Baseline to study completion (approximately 13.1 months)","title":"Duration of Clinical Benefit (DoCB) in Patients With Recurrent EEC or EOC or Carcinosarcoma (MMMT).","type":"SECONDARY","unitOfMeasure":"months"}